The board of directors of Peijia Medical Limited announced that the company, in partnership with inQB8 Medical Technologies, LLC (inQB8), has successfully completed the first patient implant in the first-in-man (FIM) clinical trial of the MonarQ Transcatheter Tricuspid Valve Replacement (TTVR) system (the System) in the world. The TTVR procedure was performed on November 21, 2022 at the Heart Centre, Rigshospitalet University Hospital, Copenhagen, Denmark, by interventional cardiologists Prof. Lars Søndergaard, M.D., Prof. Ole De Becker, M.D. and cardiothoracic surgeon Morten Smerup, M.D., Jacob Moller, M.D. (Echocardiographer), Hasse Moeller-Sorensen, M.D. (Anesthesiologist), along with inQB8 co-founder, executive Chairman, Chief Medical Officer, and cardiac surgeon, Arshad Quadri, M.D. The MonarQ TTVR system is an innovative option for treating tricuspid regurgitation. The System has a unique biodynamic attachment system that utilizes and preserves the heart's natural motion to secure the implant to the native leaflets, distribute systolic loads, and minimize paravalvular leaks over a wide range of annulus sizes.